- CITATIONS: 1
|Calculated MW||10852 Da|
|Other Names||Apolipoprotein C-III, Apo-CIII, ApoC-III, Apolipoprotein C3, APOC3|
|Target/Specificity||A synthetic corresponding to C-terminus of human Apolipoprotein CIII was used as immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Apolipoprotein CIII Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed:18201179, PubMed:22510806). Plays a multifaceted role in triglyceride homeostasis (PubMed:18201179, PubMed:22510806). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed:18201179, PubMed:22510806). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed:18201179, PubMed:22510806). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed:18408013).|
Provided below are standard protocols that you may find useful for product applications.
Apolipoprotein CIII (Apo CIII) is one of 9 known polymorphic forms of apolipoproteins. The apolipoproteins function as stabilizers of intact lipoprotein particles. Specifically, Apo CIII is a very low density lipoprotein (VLDL) protein (1). Apo CIII is involved in inhibition of lipoprotein and hepatic lipases. It is thought to delay catabolism of triglyceride-rich particles. A defect in Apo CIII has been linked to hyperalphalipoproteinemia (HLAP), which causes increased levels of high density lipoprotein (HDL) (2).
1. Hirano, T, et al; Kidney International 63:2171
2. Hirano, K, et al; Arteriosclerosis, Thrombosis, and Vascular Biology, 15:1849-1856, 1995.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.